The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden

hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0001730463	Autolus Ther	apeutics Ltd	Corporation
Name of Issuer			Limited Partnership
Autolus Therapeutics plc			
Jurisdiction of Incorporation/O	rganization		Limited Liability Company
UNITED KINGDOM			General Partnership
Year of Incorporation/Organiza	ation		Business Trust
X Over Five Years Ago			X Other (Specify)
Within Last Five Years (Sp	pecify Year)		D 11: 1: 1: 10
Yet to Be Formed	,,		Public Limited Company
2. Principal Place of Busines	s and Contact Information		
Name of Issuer			
Autolus Therapeutics plc			
Street Address 1		Street Address 2	
c/o MediaWorks		191 Wood Lane	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
London	UNITED KINGDOM	W12 7FP	(44) 20 3829 6230
3. Related Persons			
Last Name	First Name		Middle Name
Itin	Christian		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 19		
City	State/Province/Co	=	ZIP/PostalCode
London	UNITED KINGDO	M	W12 7FP
Relationship: X Executive Of	fficer X Director Promoter		
Clarification of Response (if No	ecessary):		
Last Name	First Name		Middle Name
Dolski	Robert		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 19	91 Wood Lane	
City	State/Province/Co	ountry	ZIP/PostalCode
London	UNITED KINGDO	M	W12 7FP
Relationship: X Executive Of	fficer Director Promoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name		Middle Name
Braendle	Edgar		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 19	91 Wood Lane	
City	State/Province/Co	ountry	ZIP/PostalCode
London	UNITED KINGDO	-	W12 7FP
Relationship: X Executive Of	fficer Director Promoter		

Clarification of Response (if Necess	eary):		
Last Name	First Name	Middle Name	
Brochu	David		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
		W 12 /11	
Relationship: X Executive Officer			
Clarification of Response (if Necess	eary):		
Last Name	First Name	Middle Name	
Pule	Martin		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	eary):		
Last Name	First Name	Middle Name	
Vann	Christopher		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	eary):		
L and Marina	Circl Nove	Middle News	
Last Name	First Name	Middle Name	
Rice	Brent		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane	717/7	
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	eary):		
Last Name	First Name	Middle Name	
Johnson	John	H.	
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	eary):		
Last Name	First Name	Middle Name	
Anderson	Joseph		
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: Executive Officer			
Clarification of Response (if Necess			
,		Middle Neme	
Last Name	First Name	Middle Name	

Street Address 1 Street Address 2 c/o Autolus Therapeutics plc c/o MediaWorks, 191 Wood Lane City State/Province/Country ZIP/PostalCode **UNITED KINGDOM** London W12 7FP Executive Officer X Director Promoter Relationship: Clarification of Response (if Necessary): First Name Middle Name Last Name Bain Linda Street Address 1 Street Address 2 c/o MediaWorks, 191 Wood Lane c/o Autolus Therapeutics plc State/Province/Country ZIP/PostalCode City **UNITED KINGDOM** W12 7FP London Executive Officer X Director Relationship: Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name John Berriman Street Address 1 Street Address 2 c/o MediaWorks, 191 Wood Lane c/o Autolus Therapeutics plc City State/Province/Country ZIP/PostalCode UNITED KINGDOM W12 7FP London Relationship: | Executive Officer X Director Promoter Clarification of Response (if Necessary): First Name Middle Name Last Name **Butitta** Cynthia Street Address 1 Street Address 2 c/o MediaWorks, 191 Wood Lane c/o Autolus Therapeutics plc State/Province/Country ZIP/PostalCode City UNITED KINGDOM London W12 7FP Executive Officer X Director Relationship: Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Robert Iannone Street Address 2 Street Address 1 c/o Autolus Therapeutics plc c/o MediaWorks, 191 Wood Lane State/Province/Country ZIP/PostalCode Citv UNITED KINGDOM W12 7FP London Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Elisabeth Leiderman Street Address 1 Street Address 2 c/o Autolus Therapeutics plc c/o MediaWorks, 191 Wood Lane State/Province/Country City ZIP/PostalCode London UNITED KINGDOM W12 7FP Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Murphy Martin Street Address 1 Street Address 2 c/o Autolus Therapeutics plc c/o MediaWorks, 191 Wood Lane

Azelby

Robert

City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: Executive Officer X Di	rector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Young	William	D.	
Street Address 1	Street Address 2		
c/o Autolus Therapeutics plc	c/o MediaWorks, 191 Wood Lane		
City	State/Province/Country	ZIP/PostalCode	
London	UNITED KINGDOM	W12 7FP	
Relationship: Executive Officer X Di Clarification of Response (if Necessary):	rector Promoter		
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	Biotechnology		
Commercial Banking		Restaurants	
Insurance	Health Insurance	Technology	
Investing	Hospitals & Physicians	Computers	
Investment Banking	Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as		Travel	
an investment company under	Manufacturing Real Estate		
the Investment Company Act of 1940?	Commercial	Airlines & Airports	
Yes No		Lodging & Conventions	
	Construction	Tourism & Travel Services	
Other Banking & Financial Servic	es REITS & Finance	Other Travel	
Business Services	Residential	X Other	
Energy	Other Real Estate	A Other	
Coal Mining	Uner Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
	Aggregate Nat Assat V-1	ua Panga	
Revenue Range OR No Revenues	Aggregate Net Asset Val No Aggregate Net As	_	
\$1 - \$1,000,000	\$1 - \$5,000,000	oot value	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00		
\$25,000,001 -	H		
\$100,000,000	\$50,000,001 - \$100,0	00,000	
Over \$100,000,000	Over \$100,000,000		
X Decline to Disclose	Decline to Disclose		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion	(s) Claimed (select all that apply)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Compa	ny Act Section 3(c)	
Rule 504 (b)(1)(i)			
Rule 504 (b)(1)(ii)	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(iii)	Section 3(c)(2)	Section 3(c)(10)	
r i i i i i i i i i i i i i i i i i i i			

X Rule 506(b)	Section 3(c)(3) Section 3(c)(11)	
Rule 506(c)	Section 3(c)(4) Section 3(c)(12)	
Securities Act Section 4(a)(5)	Section 3(c)(5) Section 3(c)(13)	
	Section 3(c)(6) Section 3(c)(14)	
	Section 3(c)(7)	
7. Type of Filing		
	et Sala Vet to Occur	
X New Notice Date of First Sale 2024-02-13 Final Amendment	st Sale Yet to Occur	
Amendment		
8. Duration of Offering		
Does the Issuer intend this offering to last more than	one year? Yes No	
9. Type(s) of Securities Offered (select all that app	y)	
X Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another	Security Mineral Property Securities	
Security to be Acquired Upon Exercise of Option,	Warrant or Other Other (describe)	
Right to Acquire Security	L , , ,	
10. Business Combination Transaction		
Is this offering being made in connection with a busin merger, acquisition or exchange offer?	ess combination transaction, such as a Yes X N	lo
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside inve	stor \$0 USD	
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X	None
Street Address 1	Street Address 2	_
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	tates Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$200,000 USD or	Indefinite	
Total Array at Sold \$200,000,000 USD or	Indefinite	
Total Amount Sold \$200,000,000 USD	Indefinite	
Total Remaining to be Sold \$0 USD or	Indefinite	
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or menter the number of such non-accredited investor	ay be sold to persons who do not qualify as accredited inve s who already have invested in the offering.	stors, and
Regardless of whether securities in the offering linvestors, enter the total number of investors wh	ave been or may be sold to persons who do not qualify as a already have invested in the offering:	accredited
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commission an estimate and check the box next to the amount.	and finders fees expenses, if any. If the amount of an expe	enditure is not known, provide
Sales Commissions \$0 USD Estir	ate	
Finders' Fees \$0 USD Estir	ate	

16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

Signature and Submission

In submitting this notice, each issuer named above is:

Clarification of Response (if Necessary):

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Autolus Therapeutics plc	/s/ Christian Itin	Christian Itin	Chief Executive Officer	2024-02-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.